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Essentials
• Variants at ABO, von Willebrand Factor (VWF) and
2q12 contribute to the variation in plasma in VWF.
• We performed a genome-wide association study of
plasma VWF propeptide in 3,238 individuals.
• ABO, VWF and 2q12 loci had weak or no association
or linkage with plasma VWFpp levels.
• VWF associated variants at ABO, VWF and 2q12 loci
primarily affect VWF clearance rates.
Summary. Background: Previous studies identified com-
mon variants at the ABO and VWF loci and unknown
variants in a chromosome 2q12 linkage interval that con-
tributed to the variation in plasma von Willebrand factor
(VWF) levels. Whereas the association with ABO
haplotypes can be explained by differential VWF clear-
ance, little is known about the mechanisms underlying the
association with VWF single-nucleotide polymorphisms
(SNPs) or with variants in the chromosome 2 linkage
interval. VWF propeptide (VWFpp) and mature VWF
are encoded by the VWF gene and secreted at the same
rate, but have different plasma half-lives. Therefore, com-
parison of VWFpp and VWF association signals can be
used to assess whether the variants are primarily affecting
synthesis/secretion or clearance. Methods: We measured
plasma VWFpp levels and performed genome-wide link-
age and association studies in 3238 young and healthy
individuals for whom VWF levels had been analyzed pre-
viously. Results and conclusions: Common variants in an
intergenic region on chromosome 7q11 were associated
with VWFpp levels. We found that ABO serotype-specific
SNPs were associated with VWFpp levels in the same
direction as for VWF, but with a much lower effect size.
Neither the association at VWF nor the linkage on chro-
mosome 2 previously reported for VWF was observed
for VWFpp. Taken together, these results suggest that
the major genetic factors affecting plasma VWF levels,
i.e. variants at ABO, VWF and a locus on chromosome 2,
operate primarily through their effects on VWF
clearance.
Keywords: genetic linkage analysis; genome-wide
association study; venous thromboembolism; von
Willebrand disease; von Willebrand factor.
Introduction
Plasma von Willebrand factor (VWF) levels vary approxi-
mately five-fold among healthy individuals, and are highly
heritable [1–5]. Individuals with VWF levels at the
extremes of the normal distribution are at risk for com-
mon disorders of hemostasis: low levels cause the com-
mon bleeding disorder type I von Willebrand disease
(VWD); and high levels are associated with increased
risks for both venous and arterial thrombosis [6,7]. There-
fore, identification of the genetic factors affecting VWF
levels may lead to improved, personalized care for
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patients with VWD, arterial thrombosis, and venous
thromboembolic disease [8].
Previous genome-wide association studies (GWASs)
demonstrated that common variants at ABO, VWF and
other loci explained ~ 12% of the variation in plasma
VWF levels [9]. More recently, we reported genome-wide
linkage and association analyses of plasma VWF levels in a
cohort of young healthy individuals [3], and confirmed the
association between ABO A1 and B alleles with elevated
VWF levels relative to the O and A2 alleles. At VWF, hap-
lotypes containing common variants near the factor VIII-
binding (D0 domain) and propeptide-coding (D1 and D2
domains) regions were also significantly associated with
VWF levels [3,10]. Using the sibling structure in our
cohorts, we performed linkage analysis, and identified an
interval on chromosome (Chr) 2q12 explaining ~ 19% of
the variation in VWF levels [3]. Although the effect may
not be direct [11], the major allelic variants at ABO influ-
ence VWF levels through altered VWF clearance [12–14],
whereas the basic mechanisms underlying the effect of the
variants in VWF and in Chr 2q12 remain unknown.
A specialized post-translational modification system
facilitates the storage and secretion of VWF multimers
[15]. The VWF propeptide (VWFpp) is cleaved from pro-
VWF dimers, but remains non-covalently bound to the
developing VWF multimers until both are secreted into
flowing blood. VWFpp is rapidly cleared from the circu-
lation, with a half-life of 2–3 h, whereas multimeric VWF
has a longer half-life of 8–12 h [16]. As alterations in
VWF synthesis or secretion would be expected to affect
VWF and VWFpp levels similarly, relative differences in
the steady-state levels of these two proteins in plasma
should reflect differences in their clearance rates. For this
reason, elevation in the VWFpp/VWF ratio has been used
to differentiate the subset of individuals with VWD
resulting from rapid clearance of VWF from those with
reduced synthesis or secretion [17,18].
To identify genetic variants affecting plasma VWFpp
levels and to determine whether single-nucleotide poly-
morphisms (SNPs) previously associated with VWF varia-
tion operate primarily through altered synthesis/secretion
or clearance mechanisms, we measured VWFpp levels in
plasma samples from the Genes and Blood Clotting Study
(GABC) and the Trinity Student Study (TSS), in which
VWF levels had already been measured and their associa-
tion results reported [3]. Using an initial measure of
VWFpp in the GABC cohort, we identified a strong asso-
ciation with a non-synonymous SNP in the VWFpp-cod-
ing portion of VWF. However, this association was not
present when a different set of mAbs were used to deter-
mine VWFpp levels, suggesting that an altered epitope
resulting from this SNP had generated the apparent asso-
ciation. We therefore used only VWFpp assay results
without interference from this altered epitope in associa-
tion and linkage studies, and identified significant associa-
tions between VWFpp and variants at ABO and a new
locus on Chr 7. Comparison of these results with those of
our previously reported VWF studies [3] suggest that vari-
ants at VWF and the Chr 2 linkage interval modify VWF
levels mainly through clearance mechanisms.
Materials and methods
GABC
One thousand one hundred and eighty-nine healthy sib-
lings between the ages of 14 years and 35 years were
recruited from the students and staff at the University of
Michigan, Ann Arbor between June 2006 and January
2009 [3,19]. Subjects who reported that they were preg-
nant or had a known bleeding disorder or chronic illness
requiring regular medical care were excluded. All subjects
gave informed consent prior to their participation [20].
TSS
Healthy Irish individuals aged 18–28 years, attending Trin-
ity College of the University of Dublin, were recruited
between 2003 and 2004 for genetic analysis of nutrition-
related and diet-related traits. A total of 2490 participants
completed questionnaires and donated blood samples. Eth-
ical approval from the Dublin Federated Hospitals
Research Ethics Committee was obtained and reviewed by
the Office of Human Subjects Research at the United States
National Institute of Health. Participants provided written
informed consent prior to recruitment.
Plasma VWFpp levels
VWFpp levels were measured in the GABC and TSS
cohorts with AlphaLISA (Perkin-Elmer, Waltham, MA,
USA) [3]. To create VWFpp-specific AlphaLISA assays,
mAbs were produced in the Blood Center of Wisconsin
Hybridoma Core Laboratory (Milwaukee, WI, USA) by
immunizing mice with purified recombinant human
VWFpp. mAbs were purified from ascites, and epitope
mapping was performed by the use of standard ELISAs,
with truncated fragments of recombinant VWFpp as tar-
gets (Fig. S1). For TSS plasma samples, which were col-
lected with EDTA as an anticoagulant, 0.8 mM CaCl2
was added to the assay buffer to correct for signal loss
associated with the presence of EDTA (Fig. S2).
VWFpp levels were calculated on the assumption of a
1 : 1 ratio of VWF to VWFpp in laboratory control
plasma from pooled donors (FACT; George King Bio-
medical, Overland Park, KS, USA). Each sample was inde-
pendently assayed at least four times. The mean sample
coefficients of variation were 1.0% (GABC, anti-D2), 1.1%
(GABC, anti-D1), and 2.8% (TSS, anti-D1). After quality
control, 3381 subjects (1110 GABC; 2271 TSS) had
VWFpp levels available for heritability analysis, and 3238
had them available for association and linkage testing.
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Phenotype data processing
The raw VWFpp distribution was normalized by log
transformation, and adjusted for the effects of age, gen-
der, and population genetic structure. We evaluated the
correlation between each of the first 10 principal compo-
nent (PC) scores and the age-corrected and gender-cor-
rected VWFpp levels for GABC and TSS separately, and
used Pearson’s correlation coefficients and P-values to
determine which PCs have a significant impact (P < 0.05)
on the phenotype. After analyzing Pearson’s correlation
coefficients, P-values and genomic control (GC) factors,
we selected the PC(s) that were highly correlated with the
two traits and resulted in the lowest GC factors. For use
in GWAS and linkage studies, log-transformed VWFpp
levels were adjusted for age, gender, and the selected PC
(s): PC2 and PC7 for GABC, and PC4 for TSS.
Genotyping, imputation, and quality control
GABC: Details of the genotyping and data-cleaning process
have been previously published [3,20,21]. The final cleaned
dataset contained 763 195 SNPs and 1152 subjects repre-
senting 489 sibships. Imputation was carried out by the
GENEVA Consortium Data Coordinating Center, using
BEAGLE v3.3.1 [22] on a set of 767 243 genotyped SNPs.
The final dataset included ~ 7.50 million SNPs. We then
removed SNPs with low imputation quality (R2 < 0.3) and
low allele frequency (minor allele frequency [MAF] of
< 2%), resulting in ~ 5.95 million SNPs.
TSS: After extensive cleaning, the final dataset con-
tained 757 577 SNPs.
For imputation, we first pre-phased the cleaned dataset
by using SHAPEIT2 v2.r778 [23], and then used IM-
PUTE2 v2.3.0 [24] and the 1000 Genomes Phase I
release v3 integrated haplotypes (produced by the use of
SHAPEIT2 in December 2013) for imputation. This gener-
ated 10 520 121 imputed SNPs. After removal of the
SNPs with low imputation quality (R2 < 0.3), low allele
frequency (MAF of < 2%), and low call rate (< 95%),
and that failed the test of Hardy–Weinberg equilibrium
(P < 1.0 9 106), the final dataset contained ~ 7.37 mil-
lion SNPs in 2304 individuals.
The TSS and GABC imputed datasets had ~ 4.51 mil-
lion SNPs in common; this set was used for the meta-ana-
lyses. The genome-wide significance level was set at
P = 5.0 9 108, based on a conservative Bonferroni cor-
rection for ~ 1 million independent tests.
Genetic analyses
Population substructure Owing to the presence of sib-
ships of different sizes, GABC samples were analyzed
with a two-step approach [25], as detailed previously
[3,19].
Association analyses For the GABC cohort, we per-
formed single-SNP association analysis of the transformed
and adjusted VWFpp antigen levels by using the imputed
set of ~ 5.95 million SNPs. To account for the inferred
relatedness and subtle population stratification, we applied
a mixed linear model implemented in EMMAX [26]. For the
TSS cohort, we performed single-SNP association tests on
the set of ~ 7.37 million imputed SNPs by using PLINK
(v1.07) [27], assuming an additive mode of allelic effect.
For both cohorts, we calculated the GC factor [28] to assess
the degree of residual stratification.
Meta-analysis We performed a meta-analysis of GABC
and TSS association results with a sample size-weighted
approach on the common set of ~ 4.51 million imputed
SNPs by using METAL [29]. The GC factor was near 1 for
both analyses, i.e. 0.972 and 1.013 for GABC (EMMAX)
and TSS (PLINK), respectively, and the association statis-
tics were corrected to reach a GC factor of 1.000 by the
use of METAL before being used in the meta-analysis.
Regional plots of the significant findings were produced
with LOCUSZOOM [30].
Detection of an antibody-specific SNP association with
VWFpp VWFpp levels were initially determined by
using a pair of monoclonal anti-VWFpp D2 domain anti-
bodies (Fig. S1). In the European subset (n = 934) of
GABC, a single SNP, rs1800378(T), with a MAF of 33%
in our cohort, was associated with VWFpp
(P = 1.15 9 1012, b = 0.051 IU dL1 per allele in an
additive model) (Fig. S3A–C). This SNP encodes a his-
tidine to arginine substitution at position 484 in the D2
domain of VWFpp, and is predicted by POLYPHEN-2 [31]
to be a benign variant. It was not significantly associated
with plasma VWF levels (P = 0.52). We repeated the
VWFpp measurement with a second pair of anti-VWFpp
D1 domain antibodies (Fig. S1). Although the log-trans-
formed VWFpp levels measured with the anti-D2 domain
antibodies were highly correlated with those measured
with the anti-D1 domain antibodies (Spearman’s
q = 0.97, P < 0.0001), VWFpp levels measured with the
anti-D1 domain antibodies did not produce a significant
signal at rs1800378 (P = 0.061; Fig. S3D,E), suggesting
that VWFpp bearing this coding change has altered affin-
ity for the anti-D2 domain antibody pair. We used
VWFpp levels measured with the anti-D1 domain anti-
bodies in subsequent association and linkage analyses.
Linkage analysis Linkage analysis was carried out with
MERLIN-REGRESS [32] on the European sibling subset of
GABC and the sibling subset of TSS (n = 138). We
employed a clustering algorithm and a permutation-based
locus-counting approach to calculate empirical P-values
for the top linkage signals, as previously described [3].
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Starting with the MERLIN-REGRESS output, the subsequent
analysis was carried out with custom scripts in R [33].
Heritability analysis For the combined sibling subset of
TSS and 1139 GABC individuals (557 sibships), we used
two pedigree-based methods for estimating heritability,
i.e. intraclass correlation and MERLIN-REGRESS (v1.1.2), as
previously described [3,19,32].
Variance explained by association and linkage
regions The Genome-wide Complex Trait Analysis
(GCTA) package [34] was used to estimate the proportion
of variation in VWFpp levels explained by the entire gen-
ome, the top associated SNPs, or intervals representing
individual genes or loci, as previously described [3,19].
Haplotype-based association analysis PLINK [27] was used
to carry out haplotype association with the one-degree-of-
freedom haplotype-specific test. ABO serotypes (A1, A2, O,
and B) were tagged by the three SNPs rs687289, rs8176704,
and rs8176749, as reported by Barbalic et al. [35].
Results
VWFpp levels are highly heritable
Details of the demographic characteristics of the TSS and
GABC cohorts are shown in Table 1. There were differ-
ences in the distribution of unadjusted VWFpp levels
(Fig. S4A) between the GABC and TSS cohorts (Kol-
mogorov–Smirnov test, P = 0.0001), with median VWFpp
levels of 100.0 IU dL1 in GABC and 86.1 IU dL1 in
TSS (Table 1). These differences may have resulted from
sample collection in acid citrate dextrose for GABC versus
in EDTA for TSS that was not adequately corrected for by
additions of CaCl2 to the assay buffer (see Materials and
methods). However, when the VWFpp values were log-
transformed, mean-centered within each cohort, and
adjusted for age, sex, and the population structure, the dis-
tribution differences between GABC and TSS disappeared
(Fig. S4B). On the basis of on interclass correlation among
the siblings in the GABC and TSS cohorts, the narrow-
sense heritability of VWFpp was 77.6%, consistent with
the value of 80.4% obtained with MERLIN-REGRESS. These
heritability estimates are similar to those we reported for
VWF, i.e. 64.5% and 66.3%, using interclass correlation
and MERLIN-REGRESS, respectively [3]. There was a signifi-
cant positive correlation between the adjusted VWFpp and
Table 1 Characteristics of study participants
Cohort GABC* TSS
No. of subjects (n) 1152 2304
Age (years) (Q1, Q3) 21 (19, 23) 22 (21, 24)
Female, n (%) 721 (63) 1352 (59)
Sibship size
(no. of sibships)
1 (13); 2 (366); 3 (94);
4 (22); 5 (5); 6 (2)
2 (66); 3 (2)
Median VWF level
(IU dL1) (Q1, Q3)
100.2 (77.5, 130.7) 99.8 (79.6, 128.1)
Median VWFpp level
(IU dL1) (Q1, Q3)
100.0 (82.2, 122.1) 86.1 (71.8, 104.6)
GABC, Genes and Blood Clotting Study; TSS, Trinity Student
Study; VWF, von Willebrand factor; VWFpp, von Willebrand factor
propeptide. *Data from previous VWF analysis [3], except for
VWFpp level.
Table 2 Top 15 imputed meta-analysis SNPs for VWFpp. Genome-wide significant (P-value <5.0 9 108) SNPs in GABC (EMMAX) + TSS




Allele P-value Closest gene
Allele
freq. Beta (SE) P-Value
Allele
freq. Beta (SE) P-value
rs10251762 7 68335032 T 2.9 9 108 AUTS2 0.078 0.034 (0.011) 2.9 9 103 0.065 0.034 (0.0072) 2.4 9 106
rs12531236 7 68336435 T 4.2 9 108 AUTS2 0.081 0.034 (0.010) 1.6 9 103 0.062 0.031 (0.0068) 6.3 9 106
rs10246260 7 68338971 A 2.9 9 108 AUTS2 0.078 0.034 (0.011) 2.9 9 103 0.065 0.034 (0.0072) 2.4 9 106
rs55800567 7 68340079 A 2.0 9 108 AUTS2 0.079 0.035 (0.011) 2.0 9 103 0.060 0.034 (0.0072) 2.4 9 106
rs10252976 7 68343237 T 3.7 9 108 AUTS2 0.92 0.033 (0.011) 3.9 9 103 0.93 0.034 (0.0072) 2.4 9 106
rs11977562 7 68349402 A 4.3 9 108 AUTS2 0.92 0.033 (0.011) 3.9 9 103 0.94 0.034 (0.0072) 2.8 9 106
rs56835261 7 68356258 A 1.6 9 108 AUTS2 0.92 0.035 (0.011) 2.1 9 103 0.93 0.034 (0.0072) 1.9 9 106
rs8176749 9 136131188 A 1.1 9 1013 ABO 0.070 0.052 (0.012) 2.0 9 105 0.073 0.040 (0.0066) 8.5 9 1010
rs8176746 9 136131322 A 1.0 9 1013 ABO 0.070 0.052 (0.012) 2.0 9 105 0.073 0.040 (0.0066) 8.3 9 1010
rs8176743 9 136131415 A 1.2 9 1013 ABO 0.070 0.052 (0.012) 2.0 9 105 0.073 0.040 (0.0065) 9.5 9 1010
rs8176741 9 136131461 T 1.4 9 1013 ABO 0.070 0.052 (0.012) 2.0 9 105 0.073 0.040 (0.0066) 1.1 9 109
rs8176725 9 136132617 T 1.9 9 109 ABO 0.093 0.042 (0.010) 5.7 9 105 0.099 0.026 (0.0057) 4.5 9 106
rs8176722 9 136132754 T 2.4 9 109 ABO 0.093 0.042 (0.010) 7.0 9 105 0.099 0.026 (0.0057) 4.8 9 106
rs687289 9 136137106 T 6.4 9 1010 ABO 0.36 0.023 (0.0065) 2.7 9 104 0.25 0.020 (0.0039) 4.7 9 107
rs657152 9 136139265 T 1.7 9 108 ABO 0.38 0.023 (0.0062) 1.7 9 104 0.28 0.016 (0.0038) 1.5 9 105
Chr, Chromosome; SE, Standard error. Beta values based on log transformed, adjusted VWFpp values. *Coordinates are in NCBI36/hg18.
†In the combined set of 934 individuals in the GABC and 2304 individuals in the TSS cohort.
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Fig. 1. von Willebrand factor propeptide meta-analysis results. (A) Genome-wide plot of  log10(P) values for ~ 4.51 million single-nucleotide
polymorphisms (SNPs). The dotted line marks the 1.10 9 108 threshold of genome-wide significance. (B) Regional plot for the associated
region on chromosome 9q34. (C) Regional plot for the associated region on chromosome 7q11.22. (D) Quantile–quantile plot of observed ver-
sus expected  log10(P) values for von Willebrand factor meta-analysis. The observed  log10(P) values > 7.96 are shown in red.
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VWF levels, with Spearman’s rank correlations (q) of 0.52
for the GABC cohort (P < 0.0001) and 0.53 (P < 0.0001)
for the TSS cohort, respectively (Fig. S5AB).
Common variants at ABO and Chr 7q11 are associated with
VWFpp levels
VWFpp association results for the GABC and TSS cohorts
(Fig. S3D and Fig. S6A, respectively) were combined in a
meta-analysis using a common set of ~ 4.51 million geno-
typed and imputed SNPs. Two regions with significant
associations were identified (Table 2). First, eight SNPs on
Chr 9q34 at the ABO locus showed significant associations
(Fig. 1A,B,D), with the top SNP, rs8176746
(P = 1.1 9 1013), encoding an L266M substitution in
ABO and tagging the common ABO B allele. All SNPs at
the ABO locus (N = 28) explained 7.40% of the variation
in the adjusted VWFpp levels as compared with 19.6% of
the variation in the adjusted VWF levels (Table 3). Second,
seven associated SNPs were identified on Chr 7q11.22 in
an intergenic region, with the top SNP being rs56835261
(P = 1.6 9 108) (Fig. 1C). Taken together, the 15 signifi-
cant SNPs at these two loci explained 3.50% of the varia-
tion in the adjusted VWFpp levels (Table 3). A
heterogeneity analysis of these top SNPs showed no signifi-
cant difference across the two cohorts (all with I2 = 0%
and P > 0.05). When a conditional analysis using the top
meta-analysis SNP, i.e. rs8176746, was performed, no new
signal arose at the ABO locus or elsewhere, and the signal
at Chr 7q11, i.e. rs56835261, was reduced to just below the
threshold for significance (P = 5.5 9 108).
ABO haplotypes are associated with VWFpp levels, but less
strongly than with VWF levels
Twenty-eight SNPs at the ABO locus explained 7.40% of
the variation in VWFpp levels as compared with 19.6%
of the variation in VWF levels (Table 3) [3]. A1, B, O
and A2 tagging haplotypes had the same direction of
effect in both VWFpp and VWF associations, but the
effect sizes were weaker for VWFpp than for VWF
(Table 4). The difference between the sizes of effects of
the ABO haplotype on VWF levels and VWFpp levels is
evident when the adjusted VWF and VWFpp levels are
plotted according to ABO haplotypes predicted by three
ABO SNPs [35] (Fig. 2). There were significant differences
in VWF levels between the homozygous low group (A2/
O, O/O, and A2/A2) and the homozygous high group
(B/B, A1/A1, and B/A1) (t-test, P = 4.4 9 1055), and
the homozygous high group and the heterozygous high/
low group (A2/B, B/O, A1/O, and A1/A2) (t-test,
P = 2.8 9 1010) (Fig. 2A). For VWFpp levels, signifi-
cant differences existed between the homozygous low
group and the homozygous high group (t-test,
P = 5.0 9 106), and the heterozygous high/low group
and the homozygous low group (t-test, P = 5.6 9 109),
but not between the homozygous high group and the
heterozygous high/low group (t-test, P = 0.14) (Fig. 2B).
No significant linkage signal at Chr 2q12 for VWFpp
Using the sibling subset of GABC and linkage disequilib-
rium-based 36 658 SNP clusters, we performed linkage
studies to identify additional genetic factors affecting
VWFpp levels. Unlike VWF, which had a significant link-
age signal at Chr 2q12 and Chr 9q34 (containing ABO)
[3] (Fig. 3A), VWFpp had no significant signal in the
Chr 2q12 VWF linkage interval, or at any loci elsewhere
(Fig. 3B).
Comparisons of association results of VWF and VWFpp
suggest differential clearance mechanisms for the ABO,
VWF and Chr 7 regions
If a DNA variant affected the clearance process for either
VWF or VWFpp, we would expect it to show different
association signals for VWF and VWFpp. Conversely, if
a variant affected the shared synthesis or secretion pro-
cesses for VWF and VWFpp, it would be expected to
generate similar association effect sizes and directions for
both VWF and VWFpp. Consistent with this expectation,
rs687289 and rs8176746, tagging the O and B alleles of
ABO, respectively, had a strong association with VWF
and a much weaker association with VWFpp, suggesting
that, although these ABO SNPs were associated with both
VWF traits, the difference in the magnitude of their
effects is best explained by unequal SNP effects on the
rates of clearance from the circulation. This result agrees
with the well-described ABO blood group association
with VWF clearance, but is a new finding for VWFpp
(Table 5; Fig. S7A,B).
The top SNP at the VWF locus was rs1063856, which
encodes a non-synonymous variant (T789P) in the D0
domain of VWF. However, in the VWFpp analysis, no
VWF SNPs reached genome-wide significance. rs1063856
had the same effect directions for both VWF and
VWFpp, but the effect size was greater for VWF
(Table 5; Fig. S7C), again consistent with a variant pri-
marily affecting a VWF clearance mechanism.
Table 3 Variance of adjusted VWFpp levels calculated by GCTA
and explained by combined GABC and TSS cohorts with imputed
SNPs (n = 3238)
Region VWF VWFpp
Genome-wide (All SNPs) 62.6 56.2
All Significant SNPs* 21.1 3.50
ABO† (28 SNPs) 19.6 7.40
VWF† (415 SNPs) 2.87 1.90
*Results from meta-analysis, VWFpp (15 SNPs), VWF (129 SNPs).
†All SNPs tested in the gene region.
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In the meta-analysis, seven SNPs in the intergenic
regions of Chr 7 were associated with VWFpp. These
SNPs were not significant in previous VWF GWASs [3,9],
and had a lower effect size for VWF, suggesting the pres-
ence of a variant affecting the clearance of VWFpp but
not that of VWF (Fig. S7D).
Discussion
This study reports the first heritability, linkage and gen-
ome-wide association analyses of VWFpp levels, with
comparisons with previously published linkage and asso-
ciation studies of plasma VWF measured in the same
cohorts. We found that both plasma VWF and VWFpp
levels are highly heritable quantitative traits.
In our initial analysis of the VWFpp levels measured
with a pair of anti-D2 domain antibodies, we detected a
significant association for a non-synonymous SNP in the
D2 domain of VWF. However, we determined that this
result was probably an artefact resulting from an amino
acid substitution affecting antibody binding, and not a
genuine association with VWFpp levels. Similar apparent
associations with non-synonymous SNPs in cis have been
identified for several plasma proteins in the hemostatic
system [3,36–38]. In addition, according to the NHGRI
GWAS catalog [39] (accessed on 16 December 2015), of
the 150 reported GWASs of quantitative protein traits
relying on antibody-based assays, 62 (40%) yielded signif-
icant associations with SNPs residing at the locus encod-
ing the protein under investigation. Although these SNPs
may tag variants altering the level of the corresponding
proteins, our findings with rs1800378 and VWFpp suggest
that a subset of these signals may be false positives gener-
ated by altered antibody binding affinities for the variant
protein. This finding is similar to a report of a common
VWF SNP causing altered VWF:ristocetin cofactor activ-
ity levels, but not changing VWF levels [40]. These obser-
vations also resemble the caveats reported for gene
expression quantitative trait locus (QTL) analysis, where
some cis-expression QTLs (eQTLs) may be attributable to
variants in cDNA directly affecting hybridization to
microarray probes [41,42]. The implication for the geno-
mics community is that extra caution is warranted in the
interpretation of cis-QTLs for antibody-based protein
traits. We suggest that non-synonymous SNP associations
should be replicated with alternative antibody reagents.
Many GWASs have found significant associations with
variants in intergenic regions that presumably regulate
gene expression. This study identified an association
between VWFpp and 14 SNPs in an intergenic region on
Chr 7 that were ~ 725 kb upstream from the nearest cod-
ing sequence of AUTS2. None of these SNPs affect gene
expression, according to an eQTL database [43] (accessed
Table 4 ABO haplotype association results for VWF and VWFpp
Allele Haplotype* Allele freq.
VWF VWFpp
Beta P value Beta P value
O GGC 0.72 0.100 4.1 9 10136 0.019 5.5 9 109
A1 AGC 0.16 0.110 1.6 9 10100 0.010 1.1 9 102
B AGT 0.072 0.110 1.4 9 1047 0.043 1.2 9 1013
A2 AAC 0.053 0.017 0.045 0.005 4.2 9 102
*Haplotypes based on rs687289, rs8176704 and rs8176749.
P = 2.8 × 10–10
P = 4.4 × 10–55
P = 5.0 × 10–6
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Fig. 2. Distributions of log-transformed and covariate-adjusted von
Willebrand factor (VWF) and von Willebrand factor propeptide
(VWFpp) levels in the combined Genes and Blood Clotting Study
and Trinity Student Study cohorts (N = 3238), grouped by single-
nucleotide polymorphism-derived ABO haplotype groups. P-values
show the comparisons between the homozygous high (BB, A1A1,
and BA1), heterozygous high/low (A2B, BO, A1O, and A1A2) and
homozygous low (A2O, OO, and A2A2) groups (with ‘high’ and
‘low’ defined by their adjusted VWF levels).
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on 7 January 2016). For nine of these SNPs, ‘minimal
binding evidence’ was found by RegulomeDB [44], based
on DNase-seq and transcription factor binding motif hits
(accessed on 25 January 2016); and 12 of these SNPs had
an effect on at least one regulatory motif according to
HaploReg [45] (version 4.1, accessed on 25 January
2016). There was no significant association of these SNPs
with VWF levels, which suggests that they may regulate
the expression of a factor that affects the clearance of
VWFpp from the circulation independently of VWF. As
these SNPs were detected in the meta-analysis alone, fur-
ther replication in an independent cohort is necessary for
confirmation.
ABO blood group is an established modifier of plasma
VWF levels. As other groups have reported [46,47], we
found a significant difference in VWF levels between
high group homozygotes and high/low group heterozy-
gotes, suggesting an ABO allelic dose effect altering
steady-state levels of plasma VWF, as opposed to a
clean dominant affect of A1-type and B-type antigens,
where we would expect to find no differences between
homozygous high group and high/low group heterozy-
gotes. Previous studies have failed to detect an associa-
tion between ABO blood groups and VWFpp levels
[12,48–50]. Given the sample size of 3238 individuals,
our finding of a significant association was probably
attributable to increased power as compared with earlier
studies, which had smaller sample sizes, ranging from 47
to 948 individuals. There are four potential N-linked gly-
cosylation sites on VWFpp, but no occupancy of ABO
blood group antigens on these sites has been reported
[49]. However, Groeneveld et al. [11]. recently reported a
study of VWF clearance suggesting that the genotype of
the individual is the primary determinant of ABO-asso-
ciated VWF clearance, and not the ABO glycosylation
pattern on VWF itself. If this finding applied to VWFpp
as well, then the glycosylation pattern on VWFpp would
be irrelevant. Nevertheless, the effect of the major ABO
haplotypes on VWF and VWFpp was in the same direc-
tion, suggesting a shared mechanism of action, but func-
tional studies will be required to clarify how ABO
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Figure 3. Linkage analysis results in Trinity Student Study and Genes and Blood Clotting Study siblings (n = 1065). Genome-wide LOD scores
plotted for 36 658 ‘clusters’, defined in MERLIN to model independent regions of linkage. (A) Manhattan plot von Willebrand factor (VWF)
linkage results from a previously published analysis [3]. (B) Manhattan plot of von Willebrand factor propeptide (VWFpp) linkage results.
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For the VWF SNPs, the difference in effect size
between VWF and VWFpp and the absence of significant
associations with VWFpp levels suggest that the VWF
variants operate through an altered clearance pathway(s).
Investigators have cloned and functionally characterized
many VWF mutations causing VWD [51], but common
VWF variants causing variations in VWF levels in
healthy individuals have not yet been identified or well
characterized. Previous studies by our group and others
have documented an association of VWF levels with
common variants at the VWF locus [3,9,10]. The top
VWF SNP in our meta-analysis, i.e. rs1063856(C),
encodes a missense variant in the D0 domain of VWF,
and could be a functional variant driving the association.
Our study suggests that the VWF haplotype tagged by
this SNP encodes a form of VWF with a prolonged
plasma half-life as compared with the VWF encoded by
the reference allele, and that the effect of this haplotype
on VWFpp clearance is much weaker. The precise mecha-
nism for the altered clearance of this VWF variant
remains unknown.
Linkage analysis of VWFpp did not detect a QTL at
Chr 2q12, which was previously identified as a QTL for
VWF levels. The linkage interval contains many potential
candidate genes, and our results suggest that genes poten-
tially affecting protein clearance, such as those encoding
sialotransferases (ST3GAL5) or lectin receptors
(LMAN2L), are more attractive candidates than genes
likely to affect synthesis or secretion pathways, such as
those encoding SNARE complex (VAMP5 and VAMP8)
or Golgi-associated (TGOLN2) proteins.
Our study used the comparative analysis of VWF and
VWFpp to distinguish genetic variants affecting VWF or
VWFpp clearance from those affecting synthesis and
secretion. However, as a novel strategy to interpret differ-
ential associations of two related proteins, our analyses
had several limitations. First, by necessity, the measure-
ment of VWFpp was performed with a different pair of
antibodies from those employed in the VWF assay. This
allows for differences in assay performance that may have
led to false-negative associations of VWFpp, suggesting
differential clearance mechanisms. However, this scenario
is not very likely, as the heritability of VWFpp levels was
very similar to that of VWF levels, and both traits were
measured in the same cohorts. Second, variants that were
associated with both clearance and synthesis/secretion
rates of VWFpp may have been undetectable in our anal-
ysis, e.g. a variant associated with both decreased secre-
tion rates and decreased clearance rates. Although our
results strongly suggest a clearance mechanism for the
major common modifiers of VWF, functional studies will
be required for confirmation.
Taken together, the results of our VWFpp analyses
provide new insights into the mechanism of action for
common variants (at ABO and VWF) and potentially rare
variants (in the Chr 2 lineage region) altering plasma
VWF levels, and demonstrate a newly discovered associa-
tion signal for VWFpp at Chr 7. This study is expected
to facilitate the identification of functional variants con-
trolling VWF variation, and improve our understanding
of the molecular mechanisms in individuals with bleeding
disorders resulting from low VWF levels, or in individuals
at risk for venous thromboembolic disease resulting from
elevated VWF levels [52].
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Table 5 Comparison of effect size and direction of top meta-analysis
single-nucleotide polymorphisms (SNPs) for von Willebrand factor
(VWF) and von Willebrand factor propeptide (VWFpp)
SNP
(minor allele) Chr Locus
VWF VWFpp
b* P-value* b P-value
rs687289(A)† 9 ABO 0.096 7.7E-138 0.019 1.3E-9
rs8176746(T)‡ 9 ABO 0.11 1.2E-49 0.044 1.6E-13
rs1063856(C)§ 12 VWF 0.031 6.7E-17 0.014 7.7E-6
rs56835261(A) 7 Intergenic 0.015 3.5E-2 0.035 8.5E-9
SNPs were selected for further analysis if they were the top SNPs
defining a locus in the meta-analysis for VWF [3] or VWFpp levels.
*Results from previous VWF analysis [3]. †This SNP tags the com-
mon O allele of ABO. ‡This SNP tags the common B allele of ABO.
§This SNP encodes a non-synonymous VWF variant T789P in the
D0 domain.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Fig. S1. Epitope mapping anti-VWFpp antibodies.
Fig. S2. Single-donor VWFpp AlphaLISA assay.
Fig. S3. VWFpp association analysis results in GABC.
Fig. S4. Raw and adjusted VWFpp distributions in
GABC (934 European individuals) and TSS (2304 indi-
viduals) cohorts.
Fig. S5. Scatter plot of individual log-adjusted VWFpp
and VWF levels of the (A) GABC and (B) TSS partici-
pants.
Fig. S6. VWFpp association analysis results in TSS.
Fig. S7. Distribution of log-transformed VWF and
VWFpp by top meta-analysis SNP allelic series.
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